Interim CFO appointment
HealthBeacon plc ("HealthBeacon" or "the Company"), a leader in devices and software to manage critical and chronic medications, today announces the appointment of Lar Malone as Interim Chief Financial Officer.
Lar will join HealthBeacon on Wednesday 21st December 2022, while a process to appoint a Chief Financial Officer on a permanent basis is ongoing.
A Chartered Management Accountant with significant finance and management experience in the pharmaceutical industry, including senior roles with Schering-Plough, Pfizer and Teva, Lar joins the Company from Alexion, where he was Senior Accounting Manager.
As part of the CFO transition, Laurence Flavin is stepping down as Executive Director and will be replaced as Company Secretary by HealthBeacon co-founder and CTO, Kieran Daly, with immediate effect.
Jim Joyce, Co-Founder and Chief Executive of HealthBeacon, commented: "I am very pleased to welcome Lar to HealthBeacon and look forward to working with him as he brings his excellent experience to bear within our finance function. Lar has extensive experience in the pharmaceutical industry and will be a valuable asset to the Company as our CFO succession process remains ongoing."
Ends
| Enquiries: |
|
| HealthBeacon: Jim Joyce
|
|
| Goodbody (Euronext Listing Sponsor and Broker): David Kearney |
+353 (1) 667 0420 |
| Stephen Kane |
|
|
Drury (Public Relations): |
|
| Cathal Barry |
+353 (0) 87 227 9281 |
| Paul Clifford |
+353 (0) 87 327 2161 |
About HealthBeacon
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops smart tools for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company has expanded its offering to growth management with the launch of its integrated Smart Scale and oral adherence with the launch of HB Wave which integrates with its existing technology. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home. Ends
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.